Author: Zacks Small Cap Research

1383940414250400 / 491 POSTS
By John Vandermosten, CFA NASDAQ:RXIIINITIATING COVERAGEWe are initiating coverage of RXi Pharmaceuticals Corp (NASDAQ:RXII) with a $20.00 price target based on our estimates for a 2023 launch of RXI-109 and a 2022 launch of Samcyprone, both thro ...
By David Bautz, PhDTSX:ATE.VData from Phase 2 GI Safety Study Expected Week of Mar. 19, 2018On February 26, 2018, Antibe Therapeutics Inc. (TSX:ATE.V) provided an update on the Phase 2 gastrointestinal (GI) safety study of its lead drug, ATB-346. The ...
By Steven Ralston, CFATSX:WML.VExecutive Summary• Current development effort – drilling campaign • Drilling program at the Laguna Verde Project, which commenced in early December 2017, is in the closing stages  • After the conclusion of th ...
By Lisa ThompsonNASDAQ:TSEMTowerJazz (NASDAQ:TSEM) reported its fourth quarter with revenues of $357.6 million, up 5% from a year ago and in line with expectations. This quarter concludes Tower’s most profitable and successful year ever. However, thi ...
NASDAQ:SKYYRapidly changing technology trends are transforming the way individuals and enterprises use the internet. Moreover, reflecting a growing number of high profile breaches of sensitive data, concerns about the privacy and safety of informatio ...
Biotricity (OTC:BTCY), a medical device company located in Redwood City, CA, is developing products focused on improving monitoring and treatment of chronic diseases.  The company’s flagship product, Bioflux, is a mobile cardiac telemetry (MCT) devic ...
By Steven Ralston, CFA NASDAQ:DSKESUMMARY OF RECENT EVENTSOn January 2, 2018, Daseke Inc. (NASDAQ:DSKE) announced that Belmont Enterprises (a truckload carrier dedicated to hauling residential glass) merged into Daseke’s SPD subsidiary (Smokey Point ...
By Brian Marckx, CFANASDAQ:EYEGEarlier this month EyeGate (NASDAQ:EYEG) announced top-line results of its phase IIb study evaluating the safety and efficacy of EGP-437 in patients which underwent cataract surgery with implantation of a monofocal post ...
By David Bautz, PhDNASDAQ:NBIX Business UpdateOpicapone NDA to be Filed in 1H19On Feb. 14, 2018, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the company will file a new drug application (NDA) for opicapone in the first half of 2019 foll ...
By Brian Marckx, CFANASDAQ:SBOT Q1 2018 Financial ResultsStellar (NASDAQ:SBOT) reported financial results for their fiscal 2018 first quarter ending December 31, 2017.  Revenue continues at relatively very low levels, reflecting the conclusion o ...
1383940414250400 / 491 POSTS